• Services for Regulatory ATMP Development
    Services for Regulatory ATMP Development

    Living biotherapeutics - Oncolytic viruses - AAV vectors

  • ATMP Biodistribution and Shedding Analysis
    ATMP Biodistribution and Shedding Analysis

    qPCR - CFU determination - Flow cytometry - EliSpot

  • MultiPlex miRNA Biomarker Discovery
    MultiPlex miRNA Biomarker Discovery

    Hydrogel particle-based >65-plex from small samples amounts

  • MultiPlex miRNA Clinical Profiling
    MultiPlex miRNA Clinical Profiling

    Pre-designed & custom >65-plex panels

FDA Approved Nabriva Therapeutics Lefamulin for both Oral and IV Use

Nabriva Therapeutics is a commercial-stage biopharmaceutical company engaged in the development of innovative anti-infective agents to treat serious infections​.

Nabriva Therapeutics recently published results of the LEAP2 clinical trial investigating XENLETA™ (lefamulin) as an anti-infective agent in community-acquired bacterial pneumonia (CAPB). The Nabriva publication of phase 3 clinical trial results highlights efficacy of XENLETA™ (lefamulin tablets) as novel, short-course, empiric monotherapy for adults with CABP.

Accelero has been involved in the LEAP2 phase 3 clinical trial for the development and validation of PCR assays detecting several infective pathogens in human sputum specimen.

The results have been published by Alexander E et al in the Journal of the American Medical Association (JAMA), 2019 Sep 27. doi: 10.1001/jama.2019.15468. PubMed ID: 31560372.

Save
Cookies user prefences
We use cookies to ensure you to get the best experience on our website. If you decline the use of cookies, this website may not function as expected.
Accept all
Decline all
Read more
Analytics
Tools used to analyze the data to measure the effectiveness of a website and to understand how it works.
Google Analytics
Accept
Decline